ACA is a botanical drug candidate developed to reduce pain and skin reactions associated with radiotherapy. Having completed a Phase I clinical trial, ACA demonstrates potential to improve treatment tolerance and quality of life for cancer patients undergoing radiation therapy.
ACA
Radiation-Induced Skin Injury
Radiotherapy is a cornerstone of cancer treatment, yet over 95% of patients experience radiation-induced dermatitis (RID), with 10–25% developing moderate to severe skin reactions that may impact treatment adherence and quality of life.
Current treatment options remain limited, highlighting a significant unmet need for therapies that reduce inflammation, protect skin integrity, and support tissue repair.
Market Opportunity
＊20 Million+ New Cancer Cases Annually
＊7.5 Million+ Patients Receive Radiotherapy Each Year
＊95%+ Experience Radiation-Induced Dermatitis
＊10–25% Develop Moderate to Severe Skin Reactions
Sources：
1.Iacovelli, N. A., Torrente, Y., Ciuffreda, A., Guardamagna, V. A., Gentili, M., Giacomelli, L., & Sacerdote, P. (2020). Topical treatment of radiation-induced dermatitis: Current issues and potential solutions. Drugs in Context, 9, Article 2020-4-7.
2.2.Behroozian, T., Goldshtein, D., Wolf, J. R., van den Hurk, C., Finkelstein, S., Lam, H., Patel, P., Kanee, L., Lee, S. F., Chan, A. W., Wong, H. C. Y., Caini, S., Mahal, S., Kennedy, S., Chow, E., & Bonomo, P. (2023). MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: Part 1) systematic review. eClinicalMedicine, 58, Article 101886.
3.3.Cheng, J., Dong, J., Fang, Y., Zhang, X., & Dang, X. (2026). Radiation-induced skin injury: A review of pathophysiology, assessment, management, and re-irradiation protocols. Frontiers in Oncology, 15, Article 1736717.
1.Iacovelli, N. A., Torrente, Y., Ciuffreda, A., Guardamagna, V. A., Gentili, M., Giacomelli, L., & Sacerdote, P. (2020). Topical treatment of radiation-induced dermatitis: Current issues and potential solutions. Drugs in Context, 9, Article 2020-4-7.
2.2.Behroozian, T., Goldshtein, D., Wolf, J. R., van den Hurk, C., Finkelstein, S., Lam, H., Patel, P., Kanee, L., Lee, S. F., Chan, A. W., Wong, H. C. Y., Caini, S., Mahal, S., Kennedy, S., Chow, E., & Bonomo, P. (2023). MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: Part 1) systematic review. eClinicalMedicine, 58, Article 101886.
3.3.Cheng, J., Dong, J., Fang, Y., Zhang, X., & Dang, X. (2026). Radiation-induced skin injury: A review of pathophysiology, assessment, management, and re-irradiation protocols. Frontiers in Oncology, 15, Article 1736717.